These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 18477621

  • 1. Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics.
    Bushe C, Yeomans D, Floyd T, Smith SM.
    J Psychopharmacol; 2008 Mar; 22(2 Suppl):56-62. PubMed ID: 18477621
    [Abstract] [Full Text] [Related]

  • 2. Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics.
    Bushe C, Shaw M.
    J Psychopharmacol; 2007 Sep; 21(7):768-73. PubMed ID: 17606473
    [Abstract] [Full Text] [Related]

  • 3. A review of the association between antipsychotic use and hyperprolactinaemia.
    Bushe C, Shaw M, Peveler RC.
    J Psychopharmacol; 2008 Mar; 22(2 Suppl):46-55. PubMed ID: 18477620
    [Abstract] [Full Text] [Related]

  • 4. Medical causes and consequences of hyperprolactinaemia. A context for psychiatrists.
    Holt RI.
    J Psychopharmacol; 2008 Mar; 22(2 Suppl):28-37. PubMed ID: 18477618
    [Abstract] [Full Text] [Related]

  • 5. Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis.
    Cookson J, Hodgson R, Wildgust HJ.
    J Psychopharmacol; 2012 May; 26(5 Suppl):42-51. PubMed ID: 22472310
    [Abstract] [Full Text] [Related]

  • 6. Antipsychotics and hyperprolactinaemia: clinical recommendations.
    Peveler RC, Branford D, Citrome L, Fitzgerald P, Harvey PW, Holt RI, Howard L, Kohen D, Jones I, O'Keane V, Pariente CM, Pendlebury J, Smith SM, Yeomans D.
    J Psychopharmacol; 2008 Mar; 22(2 Suppl):98-103. PubMed ID: 18477626
    [Abstract] [Full Text] [Related]

  • 7. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.
    Haddad PM, Wieck A.
    Drugs; 2004 Mar; 64(20):2291-314. PubMed ID: 15456328
    [Abstract] [Full Text] [Related]

  • 8. A review of hyperprolactinaemia and severe mental illness: are there implications for clinical biochemistry?
    Bushe CJ, Bradley A, Pendlebury J.
    Ann Clin Biochem; 2010 Jul; 47(Pt 4):292-300. PubMed ID: 20592331
    [Abstract] [Full Text] [Related]

  • 9. The evolution of hyperprolactinaemia as an entity in psychiatric patients.
    Kohen D, Wildgust HJ.
    J Psychopharmacol; 2008 Mar; 22(2 Suppl):6-11. PubMed ID: 18477616
    [Abstract] [Full Text] [Related]

  • 10. Hyperprolactinaemia in early psychosis-not only due to antipsychotics.
    Aston J, Rechsteiner E, Bull N, Borgwardt S, Gschwandtner U, Riecher-Rössler A.
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Oct 01; 34(7):1342-4. PubMed ID: 20188136
    [Abstract] [Full Text] [Related]

  • 11. Risperidone-induced symptomatic hyperprolactinaemia in adolescents.
    Holzer L, Eap CB.
    J Clin Psychopharmacol; 2006 Apr 01; 26(2):167-71. PubMed ID: 16633146
    [Abstract] [Full Text] [Related]

  • 12. Antipsychotic-induced hyperprolactinemia: a cross-sectional survey.
    Johnsen E, Kroken RA, Abaza M, Olberg H, Jørgensen HA.
    J Clin Psychopharmacol; 2008 Dec 01; 28(6):686-90. PubMed ID: 19011438
    [Abstract] [Full Text] [Related]

  • 13. [Antipsychotics and hyperpolactinaemia: pathophysiology, clinical relevance, diagnosis and therapy].
    Riecher-Rössler A, Schmid C, Bleuer S, Birkhäuser M.
    Neuropsychiatr; 2009 Dec 01; 23(2):71-83. PubMed ID: 19573500
    [Abstract] [Full Text] [Related]

  • 14. [Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance].
    Besnard I, Auclair V, Callery G, Gabriel-Bordenave C, Roberge C.
    Encephale; 2014 Feb 01; 40(1):86-94. PubMed ID: 23928066
    [Abstract] [Full Text] [Related]

  • 15. Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia.
    O'Keane V.
    J Psychopharmacol; 2008 Mar 01; 22(2 Suppl):70-5. PubMed ID: 18477623
    [Abstract] [Full Text] [Related]

  • 16. Prolactin awareness: an essential consideration for physical health in schizophrenia.
    Montejo AL.
    Eur Neuropsychopharmacol; 2008 May 01; 18 Suppl 2():S108-14. PubMed ID: 18346598
    [Abstract] [Full Text] [Related]

  • 17. Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management.
    Holt RI, Peveler RC.
    Clin Endocrinol (Oxf); 2011 Feb 01; 74(2):141-7. PubMed ID: 20455888
    [Abstract] [Full Text] [Related]

  • 18. Alcohol Use Disorders Identification Test (AUDIT) scores are elevated in antipsychotic-induced hyperprolactinaemia.
    Lawford BR, Barnes M, Connor JP, Heslop K, Nyst P, Young RM.
    J Psychopharmacol; 2012 Feb 01; 26(2):324-9. PubMed ID: 21262859
    [Abstract] [Full Text] [Related]

  • 19. Prolactin and smoking status in antipsychotic-treated patients.
    Mackin P, Waton A, Nulkar A, Watkinson HM.
    J Psychopharmacol; 2011 May 01; 25(5):698-703. PubMed ID: 20699354
    [Abstract] [Full Text] [Related]

  • 20. Significant elevations of prolactin levels in patients who shifted from conventional depot antipsychotics to long-acting risperidone.
    Lai YC, Chiou CC, Chen CH, Huang MC.
    J Clin Psychopharmacol; 2007 Oct 01; 27(5):523-4. PubMed ID: 17873693
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.